作者: Richard Skelton , Lei Zheng , Jennifer Kleponis
DOI: 10.7497/J.ISSN.2095-3941.2015.0046
关键词:
摘要: Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many patients do not respond to treatments with immune inhibitors, partly because of lack tumor-infiltrating effector T cells. Cancer vaccines may prime by inducing T-cell infiltration into tumors and signals. The combination vaccine an inhibitor function synergistically induce more effective antitumor responses, clinical trials test currently ongoing.